Autres langues Raphael Pharmaceutical Inc.

Actions

RAPH

US27785B2088

Recherche biotechnologique et médicale

Temps réel OTC Markets 15:48:29 15/12/2025			Varia. 5j.	Varia. 1 janv.
1,400 ^USD	+40,00%		-.--%	-

14/08	Raphael Pharmaceutical Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
17/07	Raphael Pharmaceutical Inc. annonce des démissions au sein de son conseil d'administration	CI

Autres langues

14/08	Raphael Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
17/07	Raphael Pharmaceutical Inc. Announces Board Resignations
17/07	Raphael Pharmaceutical Inc. Announces Chief Financial Officer Changes, Effective July 16, 2026
14/05	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
31/03	Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Raphael Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt
24/03	Raphael Pharmaceutical Inc. Announces Cessation of Yehuda Eliya from Board of Directors, Effective December 31, 2025
17/11	Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
17/11	Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis
13/11	Raphael Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
13/08/25	Raphael Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
11/08/25	Raphael Pharmaceutical Inc. Announces Directorate Changes
11/08/25	Raphael Pharmaceutical Inc. Completes Its Product Development and Is Ready to Launch Its Proprietary Natural Formula Under the Raphawell Brand for Rheumatoid Arthritis Support in the United States
15/05/25	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
31/03/25	Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
31/03/25	Raphael Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt
14/01/25	Raphael Pharmaceutical Inc. Announces Board Changes
07/01/25	Raphael Pharmaceutical Inc. Announces Positive Proof-Of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
07/01/25	Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
30/12/24	Raphael Pharmaceutical Inc. Receives Clinical Study Results After Successful Completion of a Proof-Of-Concept Clinical Study
14/11/24	Raphael Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
12/08/24	Raphael Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
09/07/24	Raphael Pharmaceutical Issues Letter to Shareholders
26/06/24	Raphael Pharmaceutical : Certificate of Incorporation/Bylaws Form 8 K
15/05/24	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024